Protein Adduct-Trapping by Hydrazinophthalazine Drugs: Mechanisms of Cytoprotection Against Acrolein-Mediated Toxicity

• Published in: Molecular pharmacology 2004-03, Vol.65 (3), p.655-664
• Main Authors: Burcham, Philip C., Fontaine, Frank R., Kaminskas, Lisa M., Petersen, Dennis R., Pyke, Simon M.
• Format: Article
• Language: English
• Subjects: Acrolein - antagonists & inhibitors; Acrolein - chemistry; Animals; Antihypertensive Agents - pharmacology; Cells, Cultured; Cytoprotection; Drug-Related Side Effects and Adverse Reactions; Hepatocytes - drug effects; Hydralazine - pharmacology; Mice; Protective Agents - pharmacology; Proteins - chemistry; Proteins - metabolism
• ISSN: 0026-895X; 1521-0111
• DOI: 10.1124/mol.65.3.655

Acrolein is a highly toxic aldehyde involved in a number of diseases as well as drug-induced toxicities. Its pronounced toxicity reflects the readiness with which it forms adducts in proteins and DNA. As a bifunctional electrophile, initial reactions between acrolein and protein generate adducts containing an electrophilic center that can participate in secondary deleterious reactions (e.g., cross-linking). We hypothesize that inactivation of these reactive protein adducts with nucleophilic drugs may counteract acrolein toxicity. Because we previously observed that 1-hydrazinophthalazine (hydralazine) strongly diminishes the toxicity of the acrolein precursor allyl alcohol, we explored the possibility that hydralazine targets reactive acrolein adducts in proteins. We report that hydralazine abolished the immunoreactivity of an acrolein-modified model protein (bovine serum albumin), but only if the drug was added to the protein within 30 min of commencing modification by acrolein. The ability of a range of carbonyl-trapping drugs to interfere with “early” events in protein modification strongly correlated with their protective potencies against allyl alcohol toxicity in hepatocytes. In mass spectrometry studies using a model lysine-containing peptide, hydralazine rapidly formed hydrazones with Michael adducts generated by acrolein. Using an antibody raised against such ternary drug-acrolein-protein complexes in Western blotting experiments, clear adduct-trapping was evident in acrolein-preloaded hepatocytes exposed to cytoprotective concentrations of hydralazine ranging from 2 to 50 μM. These novel findings begin to reveal the molecular mechanisms whereby hydralazine functions as an efficient “protein adduct-trapping” drug.